SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood is trending as retail investors react to a combination of workforce restructuring, record-breaking trading volumes, and bullish anticipation for new revenue streams like AI-driven trading tools and prediction markets. Community members are actively debating the stock's potential for a breakout, with many focusing on the impact of increased platform engagement during major sporting and market events.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors closely monitor a high-stakes legal dispute with Nippon Shinyaku regarding the distribution rights for its Duchenne muscular dystrophy therapy, Deramiocel. The community is actively discussing the impact of this litigation on the upcoming August PDUFA date, with many bullish investors framing the lawsuit as a strategic catalyst that could return full commercial rights to Capricor ahead of the drug's anticipated approval.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant institutional interest as the community anticipates imminent Phase 3 52-week data, which is widely viewed as a major catalyst for potential M&A activity. Traders are actively discussing the stock's tight float and the strategic significance of recent supply agreements alongside upcoming conference presentations.

Fermi, Inc. engages in the development of energy infrastructure. It intends to develop an energy and data center development campus to support the needs of to-be-built AI infrastructure. The company was founded by Rick Perry, Toby Neugebauer and Griffin Perry on January 10, 2025 and is headquartered in Amrillo, TX.

Fermi Inc

Fermi LLC

Fermi LLC is experiencing heightened trading volume and volatility as investors speculate on potential data center tenant agreements amid ongoing boardroom leadership conflicts. Community sentiment remains polarized, with some traders optimistic about the company's energy infrastructure assets while others are wary of the persistent management drama and the lack of confirmed commercial contracts.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCX is experiencing significant volatility as market participants debate the stock's massive valuation and its status as a high-profile IPO. The community is sharply divided, with many retail investors expressing concerns over a potential "rug pull" and long-term downside, while others view the pullback as a buying opportunity.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is facing intense community skepticism and frustration as the stock continues to trade near all-time lows despite sustained revenue generation. Investors are actively debating potential buyout scenarios and the impact of the company's siRNA pipeline while pointing to perceived management incompetence and heavy short interest as primary drivers of recent volatility.

uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.

uniQure N.V.

uniQure NV

uniQure is surging after the FDA reversed its previous stance and now allows the company to use three-year Phase I/II data for an accelerated approval BLA filing, effectively pulling forward the commercialization timeline for its Huntington's disease gene therapy. The community is actively discussing the significant regulatory win and the potential for a rapid re-rating, with traders highlighting the strategic importance of the ClearPoint navigation system to the procedural rollout.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

The SPDR S&P Biotech ETF is trending as investors rotate back into the sector, bolstered by a wave of M&A activity and positive data readouts for key oncology therapies. The community is actively discussing the potential for a sustained breakout, while closely monitoring clinical trial milestones and regulatory updates that act as primary catalysts for the ETF's performance.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X Shares

LABD is experiencing heightened trading activity as the community remains divided over whether to capitalize on the biotech sector's volatility through short-term scalp trades or hold despite significant losses from the ETF's prolonged decline. Discussions are centered on the upcoming influence of key economic figures like Kevin Warsh, the impact of XBI's technical channel breakouts, and the recurring behavioral patterns traders are attempting to exploit during this period of market uncertainty.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean (RIG) is trending as investors react to a significant influx of contract awards that have bolstered its backlog to over $7 billion, signaling a strong offshore market recovery despite ongoing geopolitical volatility. Community discussion is heavily focused on the companys deleveraging progress, the strategic implications of the Valaris acquisition, and the potential for a short squeeze as traders weigh strong operational fundamentals against remaining sector risks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full...

These Are the Stocks Traders Are Watching into the Close

As the market enters the final stretch of trading, one story is dominating virtually every trading desk on Wall Street: the historic debut of SpaceX. The company's long-awaited public offering has generated extraordinary volume, massive investor interest, and renewed enthusiasm across multiple high-growth sectors including space infrastructure, artificial intelligence, biotechnology, and advanced communications. $NTHI, $SPCX, $ELVN, $POET, $RNAC, $ALOY

ELVN Stock On Track For Best Week Since March Following FDA-Aligned Path For Cancer Drug Development

Equity

As of March 2026, ELVN-001 produced meaningful responses in heavily pretreated patients, many of whom had already tried multiple existing therapies, Enliven Therapeutics said.


Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants PR Newswire BURLINGAME, Calif., June 11, 2026 BURLINGAME, Calif., June 11, 2026...

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants Enliven Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants PR Newswire BURLINGAME, Calif., June 11, 2026 BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven...

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components

Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components Enliven Therapeutics Announces Updated Positive Phase 1 Clinical Data and Alignment with FDA on Key Phase 3 Trial Design Components PR Newswire BURLINGAME, Calif...

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress

Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress PR Newswire BURLINGAME, Calif...

Enliven Therapeutics' Chief Medical Officer Sold 5,000 Company Shares. Here's What That Means for Investors.

Key PointsChief Medical Officer Helen Collins sold 5,000 shares of Common Stock for a total of ~$199,000 on May 18, 2026, at an average price of around $39.79 per share...

Enliven Therapeutics to Present at Upcoming Investor Conferences

Enliven Therapeutics to Present at Upcoming Investor Conferences Enliven Therapeutics to Present at Upcoming Investor Conferences PR Newswire BOULDER, Colo., May 21, 2026 BOULDER, Colo., May 21, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a...

ELVN Stock Climbs As Guggenheim Launches Coverage With $80 Price Target Ahead Of Conference Data Unveil

Enliven said that updated positive early-stage data for its lead candidate ELVN-001 will be featured in an oral presentation at the EHA 2026 Congress in Stockholm. 

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery and development of small molecule therapeutics. Its pipeline includes BCR-ABL Program: ELVN-001and HER2 Program: ELVN-002. The company was founded by Samuel S. Kintz, Joseph P. Lyssikatos, and Anish Patel on June 1, 2019 and is headquartered in Boulder, CO.

Enliven Therapeutics Inc

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

ELVNEnliven Therapeutics Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ELVN News